当地时间4月15日，Mural Oncology宣布终止其新型免疫疗法nemvaleukin的所有临床开发计划，并裁员90%。该决定是在对黑色素瘤II期ARTISTRY-6研究和铂耐药卵巢癌III期ARTISTRY-7研究数据进行评估后做出的。尽管这一壮举似乎相当反常，但Mural的股价却强劲上涨，收盘时飙升134%至4152.01万美元。

The writing is on the wall at Mural Oncology. Responding to clinical data, the biotech is laying off 90% of its employees and ...

Boston and Dublin biotech Mural Oncology is laying off nearly all of its employees and ending clinical development of its ...

please reach out to the Fierce Biotech editorial team and let us know. April 15 - Mural Oncology: The cancer-focused company is laying off 104 people—equivalent to 90% of its workforce—and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Cardiff Oncology, Inc. (NASDAQ:CRDF) stands against other hot biotech stocks ...

BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- General Oncology, Inc ... Abid brings over 20 years of experience in the biotechnology sector with expertise in financial strategy and corporate ...

Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last ...

As of April 8, 2025, the company faces both significant challenges and potential opportunities that could shape its future in the competitive oncology landscape. BioAtla’s financial performance ...

BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- General Oncology, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class medicines for metastatic cancers, today announced ...